https://www.selleckchem.com/pr....oducts/lonafarnib-sc
032). After building risk classes I to IV (p less then 0.0001), mean bRFS was 36.3 months (95% CI 32.4-40.1) in class I (PSA less then 0.8 ng/mL, no BM) and 25.8 months (95% CI 22.5-29.1) in class II (PSA ≥ 0.8 ng/mL, no BM, no VM). LR and/or pelvic LNs caused relapse in classes I and II. Mean bRFS was 16.0 months (95% CI 12.4-19.6) in class III (PSA irrelevant, present BM) and 5.7 months (95% CI 2.7-8.7) in class IV (PSA ≥ 0.8 ng/mL, no BM, present VM). CONCLUSION We developed and internally validated a risk classificati
Like
Comment
Share
